|
Laronidase
resources
|
|
|
|
|
|
DRUG INFO
Laronidase
Drug Name:
Laronidase
Indication: For treatment of mucopolysaccharidosis
Pharmacology: Laronidase is used to treat mucopolysaccharide storage disorders (specifically mucopolysaccharidosis 1 or Hurlers syndrome) caused by deficiencies of alpha-L-iduronidase. Reduced or absent a-L-iduronidase activity results in the accumulation of the GAG substrates, dermatan sulfate and heparan sulfate, throughout the body and leads to widespread cellular, tissue, and organ dysfunction.
Mechanism Of Action: Laronidase catalyses the hydrolysis of terminal alpha-L-iduronic acid residues of dermatan sulfate and heparin sulfate.
Drug Category: Enzyme replacement; enzymes (44:00.00)
Brand Names/Synonyms: Alpha-L-iduronidase precursor; Aldurazyme (Biomarin Pharmaceuticals)
Dosage Forms: SOLUTION
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: Human alpha-L-iduronidase
Chemical Formula: C3160H4848N898O881S12
Half Life: 1.5-3.6 hrs
Drug Type: Approved Drug
# Accession No: BIOD00008
CAS Registry Number: 50378-38-2; 210589-09-6
|
|
|
|
|
|
Laronidase News
(When available)
GENZYME: Genzyme Reports 22 Percent Increase in Fourth-Quarter ... Jan 12, 2006
Webbolt Business News (subscription), Sales of Aldurazyme(R) (laronidase) enzyme replacement therapy for MPS I were $21 million in the fourth quarter, up 31 percent compared with $16 million in the ...
Genzyme Reports 22 Percent Increase in Fourth-Quarter Revenue Jan 10, 2006
Oxfordshire Bioscience Network (press release), Sales of Aldurazyme® (laronidase) enzyme replacement therapy for MPS I were $21 million in the fourth quarter, up 31 percent compared with $16 million in the ...
Schaeffer's Top and Bottom Ranked Stocks (BMRN, ELNK, LGF) Jan 12, 2006
Schaeffers Research, The company's orphaned medications are Aldurazyme, which was the first drug approved by the US and European Union to treat mucopolysaccharidosis I, or Hurler ...
BioMarin Establishes Commercial Operations in Europe Jan 10, 2006
PR Newswire (press release), ...include Naglazyme(TM) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, Aldurazyme(R) (laronidase ...
BioMarin Establishes Commercial Operations in Europe Jan 10, 2006
Yahoo! News (press release) Naglazyme(TM) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, Aldurazyme® (laronidase) for ...
Manager favors Foundry Networks, BioMarin Dec 29, 2005
MSN Money Its Aldurazyme (developed through a joint venture with Genzyme), is the first drug approved in the United States and Europe to specifically treat the life ...
Rare-disease sufferers want drugs fast-tracked Dec 29, 2005
The Japan Times, Genzyme has applied to the ministry for approval of the drug, marketed under the name aldurazyme, and if all goes well it probably will be on the market here ...
|
|
|
